Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s 'Key Ingredient' For Growth: Biosimilars

Executive Summary

Teva has conducted due diligence on 36 biosimilar companies with the aim of signing a partner soon to fill a critical gap in its generics pipeline.

Advertisement

Related Content

Tymlos Inclusion Stands Out As Express Scripts Reveals 2018 Formulary
Biosimilar Dealmaking Moves The Needle Forward
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
Teva Seeds OTC Growth Synergies With Former Allergan Business
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Teva CEO Vigodman Reveals A First Glimpse At His Strategy
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel